Clinical Trials List
2023-02-01 - 2025-12-31
Phase III
Recruiting5
Terminated1
ICD-10E78.1
Pure hyperglyceridemia
ICD-9272.1
Pure hyperglyceridemia
-
Trial Applicant
MEDPACE TAIWAN LIMITED
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- 洪大川 Division of Cardiovascular Diseases
- 陳律安 Division of Neurology
- 簡禎彥 Division of Cardiovascular Diseases
- 林肇鋒 Division of Cardiovascular Diseases
- 林書毅 Division of Cardiovascular Diseases
- 陳俊延 Division of Cardiovascular Diseases
- 劉俊傑 Division of Cardiovascular Diseases
- 吳懿哲 Division of Cardiovascular Diseases
- 李俊偉 Division of Cardiovascular Diseases
- 洪崇烈 Division of Cardiovascular Diseases
- 程崇偉 Division of Cardiovascular Diseases
- 蘇正煌 Division of Cardiovascular Diseases
- 李應湘 Division of Cardiovascular Diseases
- 郭任遠 Division of Cardiovascular Diseases
- 廖峰慶 Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Mei Yueh Lee Division of Endocrinology
- 吳韋璁 Division of Cardiovascular Diseases
- Ye-Hsu Lu Division of Cardiovascular Diseases
- Po-Chao Hsu Division of Cardiovascular Diseases
- 洪薇雯 Division of Endocrinology
- Chun-Yuan Chu Division of Cardiovascular Diseases
- 趙敏芳 未分科
- Jui-Sheng Hsu Division of Radiology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 周宣彣 Division of Cardiovascular Diseases
- Ju-Yi Chen Division of Cardiovascular Diseases
- Ting-Hsing Chao Division of Cardiovascular Diseases
- 杜業豐 未分科
- Po-Sheng Chen Division of Cardiovascular Diseases
- Shih-Hung Chan Division of Cardiovascular Diseases
- Cheng-Han Lee 未分科
- 林景翰 Division of Cardiovascular Diseases
- 黃睦祥 Division of Cardiovascular Diseases
- Yen-Wen Liu Division of Cardiovascular Diseases
- Po-Tseng Lee 未分科
- 張獻元 Division of Cardiovascular Diseases
- 黃鼎鈞 Division of Cardiovascular Diseases
- Horng-Yih Ou Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
50 participants
-
Global
390 participants
